Stock Quote
Keryx Biopharmaceuticals, Inc. (KERX.W) (NASD ADF)
$2.16
11 Nov 2009
-2.26%
$2.21
$2.16
100
$2.16
$2.16
$3.33
$0.09
3.58
998,391
KERX.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Tarnok, Michael | Interim Chairman of the Board | -- |
| Bentsur, Ron | Chief Executive Officer, Director | 1,672,127 |
| Oliviero, James | Chief Financial Officer, Treasurer, Corporate Secretary | 511,433 |
Profile
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening including renal disease and cancer. The Company is developing Zerenex (ferric citrate), an oral,... Full Description
Company Address
Keryx Biopharmaceuticals, Inc.
750 Lexington Avenue
New York NY 10022
P: +1212.5315965
750 Lexington Avenue
New York NY 10022
P: +1212.5315965
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Genzyme Corporation | $50.50 | +0.45 |
| Fresenius Medical Care AG & Co. (ADR) | $53.46 | +0.42 |
| Shire Plc. | £1,159.00 | +24.00 |
| KERX.W | Industry | |
|---|---|---|
| P/E(TTM) | 9.90 | 12.80 |
| P/S(TTM) | 5.05 | 29.90 |
| ROI(TTM) | 37.09 | 2.35 |
| ROE(TTM) | 64.26 | 3.59 |
| Consensus Recommendation | Buy |
|---|---|
| EPS Est. (Current Period) | -0.06 |
| EPS Est. (Current Year) | 0.22 |
| Total Revenue | $3.50M |
| Net Income | $0.56M |
| EPS | $0.01 |
